PSEN1 and Atrophy: Furthermore, previous studies in ADAD patients have shown thalamic hypometabolism 20 years before estimated symptom onset7 and atrophy on average 6 years before symptom onset52 in asymptomatic PSEN1 mutation carriers, suggesting that the thalamus may also be involved in early disease mechanisms in ADAD patients.